On July 2nd, Yang Il-woo, a researcher at Samsung Securities, stated, "We expect SK's stock price to strengthen because the holding company's market capitalization is anticipated to reflect the increase in NAV with high elasticity. The reasons are: 1) SK Pharmteco, a CMO company and a 100% subsidiary of SK, is expected to benefit from the improved performance of SK Biopharm; 2) SK Biopharm's strong performance is judged to be an opportunity to expect future CMO investments in biopharmaceuticals by SK; 3) Although small in scale, synergies are also expected between other bio companies invested by SK, such as Standigm, and SK Biopharm." He set the target price for SK at 388,000 KRW.
Over the past five days, individual investors have net purchased 590,583 shares of SK, while foreigners and institutions have net sold 935,858 shares and net purchased 346,013 shares, respectively.

※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

